I-BET151 (GSK1210151A) is primarily used in research and development for its role as a BET bromodomain inhibitor. It is studied for its potential therapeutic applications in cancer treatment, as it can disrupt the function of proteins involved in regulating gene expression, particularly in cancer cells. This compound is also explored in the context of inflammatory diseases, as it may modulate immune responses by targeting specific pathways. Additionally, I-BET151 is utilized in preclinical studies to better understand epigenetic mechanisms and their influence on disease progression. Its application in drug discovery aims to develop targeted therapies for conditions driven by abnormal gene expression.